Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ono Pharmaceutical Co. Ltd.

www.ono.co.jp

Latest From Celgene Corp.

Celgene Eases Angst Over Otezla, Sets The Stage For Growth

Celgene reported second quarter sales growth for key assets in its commercial portfolio, including a recovery for Otezla, and prepared investors for a deluge of data in the second half of 2017.

Sales & Earnings Business Strategies

2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck, AbbVie & Sanofi

PD-1 inhibitor performance and the intense curiosity around AstraZeneca both for its MYSTIC trial and Soriot's faithfulness to the company are key themes at the half-year mark. Eyes are also on commercial performance for Roche's Ocrevus and Merck's anacetrapib for clarity on whether it has a commercial future.

Sales & Earnings Business Strategies

Lilly, Nektar Partner On 'Stimulating' IL-2 Drug In Autoimmune Diseases

Nektar taps into Lilly's immunology know-how for fast development of NKTR-358, which targets IL-2 to stimulate the body's own inflammation-inhibiting Tregs rather than suppress the immune system.

Deals Business Strategies

Interview: Beigene Bursts Onto World IO Scene With Celgene Onboard (Part 2)

Howard Liang comes from an investment background with years of experience honed being the former managing director and head of biotech equity research at Leerink Partners. He became Beigene's CFO and Chief Strategy Officer in 2015 as the biotech prepared for its initial public offering (IPO) on Nasdaq, and has since seen the Beijing-based firm leap onto the world stage with differentiated immuno-oncology and BTK inhibitor assets.

Commercial BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Ono Pharmaceutical Co. Ltd.
  • Senior Management
  • Gyo Sagara, Pres. & CEO
    Hiroshi Awata, Exec. Dir., Clinical Dev.
  • Contact Info
  • Ono Pharmaceutical Co. Ltd.
    Phone: (81) 6 6263 5670
    8-2 Kyutaromachi 1-Chome
    Chuo-ku
    Osaka, 541-8564
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register